Montelukast
This medication blocks leukotriene receptors, reducing airway inflammation and constriction in the lungs and relieving allergy symptoms in the nose and skin. It is taken once daily by mouth to prevent asthma attacks and treat allergic rhinitis and hives.
Molekularmasse
586,1800 g/mol
LogP
7,70
TPSA
95,70 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Selective leukotriene D4 receptor antagonist.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective leukotriene D4 receptor antagonist.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
InChI
InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
Molecular Formula
C35H36ClNO3S
HBD / HBA
2 / 5
Rotierbare Bindungen
12
Schwere Atome
41
Phenytoin, a potent CYP inducer, can increase the metabolism of montelukast, potentially reducing its plasma levels and therapeutic efficacy.
Fluconazole inhibits CYP2C8-mediated metabolism of montelukast, modestly increasing montelukast plasma concentrations; the clinical impact is generally minor given montelukast's wide therapeutic index.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This medication blocks leukotriene receptors, reducing airway inflammation and constriction in the lungs and relieving allergy symptoms in the nose and skin. It is taken once daily by mouth to prevent asthma attacks and treat allergic rhinitis and hives.
Selective leukotriene D4 receptor antagonist.
Key pharmacokinetic parameters for Montelukast: Half-life: 2.7-5.5 hours.
Yes, Montelukast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL787. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5281040. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="montelukast"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/montelukast/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/montelukast/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/montelukast/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="montelukast"></drugfyi-drug>